All In Biotech

Drug Trial Radar · NCT07553663

Evaluating the Pharmacokinetics and Safety of Miricorilant

A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

14

Actual

Start

Apr 30, 2026

Primary completion

Sep 22, 2026

Study completion Sep 22, 2026

Sponsor

Lead sponsor
Corcept TherapeuticsIndustry
Sponsor type
Industry
First posted
Apr 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Conditions

  • Nonalcoholic Steatohepatitis (NASH)
  • Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
  • Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
  • Non-alcoholic Fatty Liver Disease (NAFLD)

Interventions

  • MiricorilantDrug

    Single dose of 60 mg miricorilant

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of miricorilant PK parametersTime frame: Day 1- Day 4
  2. Assessment of miricorilant PK parametersTime frame: Day 1 - Day 4
  3. Assessment of miricorilant PK parametersTime frame: Day 1 - Day 4
  4. Assessment of miricorilant PK parametersTime frame: Day 1 - Day 4
  5. Assessment of miricorilant PK parametersTime frame: Day 1 - Day 4
  6. Assessment of miricorilant PK parametersTime frame: Day 1 - Day 4
  7. Assessment of miricorilant PK parametersTime frame: Day 1 - Day 4
  8. Assessment of miricorilant PK parametersTime frame: Day 1 - Day 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site# 433

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.